Left ventricular myocardial hypertrophy and its prognostic role at chronic kidney disease
- Authors: Gendlin GE1, Shilo VY.1, Tomilina NA1, Storozhakov GI1, Borisovskaya SV1, Ettinger OA1, Badaeva SV1, Gavryushina OA1, Gendlin GE1, Shilo VY.1, Tomilina NA1, I Storogakov G1, Borisovskaya SV1, Ettinger OA1, Badaeva SV1, Gavryushina OA1
-
Affiliations:
- Issue: No 1 (2009)
- Pages: 22-28
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245799
- ID: 245799
Cite item
Full Text
Abstract
About the authors
G E Gendlin
V Yu Shilo
N A Tomilina
G I Storozhakov
S V Borisovskaya
O A Ettinger
S V Badaeva
O A Gavryushina
G E Gendlin
V Yu Shilo
N A Tomilina
G I Storogakov
S V Borisovskaya
O A Ettinger
S V Badaeva
O A Gavryushina
References
- Kannel WB, Gordon T, Offut D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham Study. Ann Intern Med 1969;71:89-105.
- Sheridan DJ. Left Ventricular Hypertrophy. Churchill Livingstone 1998.
- Levy D, Garrison RG, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl J Med 1990;322(22):1561-66.
- Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114(5):345-52.
- Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
- Verdecchia P, Garini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001;38(7):1829-35.
- Gueyffier F, Boissel JP, Pocock S, et al. Identification of risk factors in hypertensive patients. Circulation 1999;100(18):88-94.
- Devereux RB, Vakili BA, Okin PM. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001;141:334-41.
- Foley RN, Parfrey PS, Harnett JD. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Amer Soc Nephrol 1995;5:2024-31.
- Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 2002;40(6):1202-10.
- Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004;19(7):1829-34.
- Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int 2004;65:1492-98.
- Kessler M, Zannad M, Lehert P, et al. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. Nephrol Dial Transplant 2007;22(12):3573-79.
- Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16(6):1803-10.
- Paoletti E, Cannella G. Left ventricular hypertrophy in chronic kidney disease. G Ital Nefrol 2006;23(6):560-68.
- Перекокин Ю.Н., Шило В.Ю., Гендлин Г.Е. и др. Скорость пульсовой волны и податливость аорты у больных на программном гемодиализе: связь с факторами риска, кальцинозом сердца и показателями внутрисердечной гемодинамики // Нефрология и диализ. 2004. Т. 6. № 1. С. 62-69.
- Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). М., 2004.
- London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759-67.
- Zannad F, Kessler M, Grunfeld JP, et al. FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. Fundam Clin Pharmacol 2002;16(5):353-60.
- Coletta AP, Cleland JG, Freemantle N, et al. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail 2004;6(5):673-77.
Supplementary files
